The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
Open accessAbstract
Although chimeric antigen receptor (CAR) T cell therapy represents a transformative immunotherapy, it is also associated with distinct toxicities that contribute to morbidity and mortality. In this systematic review and meta-analysis, we searched MEDLINE, Embase and CINAHL (Cochrane) for reports of nonrelapse mortality (NRM) after CAR T cell therapy in lymphoma and multiple myeloma up to March 2024. After extraction of causes and numbers of death, we analyzed NRM point estimates using random-effect models. We identified 7,604 patients across 18 clinical trials and 28 real-world studies. NRM point estimates varied across disease entities and were highest in patients with mantle-cell lymphoma (10.6%), followed by multiple myeloma (8.0%), large B cell lymphoma (6.1%) and indolent lymphoma (5.7%). Entity-specific meta-regression models for large B cell lymphoma and multiple myeloma revealed that axicabtagene ciloleucel and ciltacabtagene autoleucel were independently associated with increased NRM point estimates, respectively. Of 574 reported nonrelapse deaths, over half were attributed to infections (50.9%), followed by other malignancies (7.8%) and cardiovascular/respiratory events (7.3%). Conversely, the CAR T cell-specific side effects, immune effector cell-associated neurotoxicity syndrome/neurotoxicity, cytokine release syndrome and hemophagocytic lymphohistiocytosis, represented only a minority of nonrelapse deaths (cumulatively 11.5%). Our findings underline the critical importance of infectious complications after CAR T cell therapy and support the comprehensive reporting of NRM, including specific causes and long-term outcomes. In a systematic review and meta-analysis of nonrelapse mortality (NRM) following CAR T cell treatment in 7,604 patients with lymphoma and myeloma, almost half of cases were atrributable to infections and NRM estimates varied across both tumor types and CAR T cell products
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
Two-sided confidence intervals for the single proportion: comparison of seven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e · Cited by 5,107
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109 · cited 1×
“1) 113,114 .”
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31366-0 · Cited by 2,430
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Improved tests for a random effects meta‐regression with a single covariate
Knapp, G., & Hartung, J. (2003) · Statistics in Medicine · doi:10.1002/sim.1482 · Cited by 2,075 · cited 1×
“Individual model coefficients and respective CIs were tested using the Knapp–Hartung method 119 .”
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914347 · Cited by 1,862
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
Self-citationAxicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116133 · Cited by 1,607
Self-citationMethodological quality of case series studies: an introduction to the JBI critical appraisal tool
Munn, Z., Barker, T. H., Moola, S., Tufanaru, C., Stern, C., McArthur, A., Stephenson, M., & Aromataris, E. (2019) · JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-d-19-00099 · Cited by 1,581
Controlling the risk of spurious findings from meta-regression
Higgins, J. P. T., & Thompson, S. G. (2004) · Statistics in Medicine · doi:10.1002/sim.1752 · Cited by 1,267 · cited 1×
“The stability of model estimates was validated by performing permutation testing 120 .”
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
Müller, F., Taubmann, J., Bucci, L., Wilhelm, A., Bergmann, C., Völkl, S., Aigner, M., Rothe, T., Minopoulou, I., Tur, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2308917 · Cited by 1,095
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303379 · Cited by 827
Shah, B. D., Ghobadi, A., Oluwole, O. O., Logan, A. C., Boissel, N., Cassaday, R. D., Leguay, T., Bishop, M. R., Topp, M. S., Tzachanis, D., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01222-8 · Cited by 820
Self-citationNastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02104 · Cited by 801
Kamdar, M., Solomon, S. R., Arnason, J., Johnston, P. B., Glass, B., Bachanova, V., Ibrahimi, S., Mielke, S., Mutsaers, P., Hernandez-Ilizaliturri, F., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00662-6 · Cited by 799
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213614 · Cited by 781
Jacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00591-x · Cited by 666
Martin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663
Deng, Q., Han, G., Puebla-Osorio, N., Ma, M. C. J., Strati, P., Chasen, B., Dai, E., Dang, M., Jain, N., Yang, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1061-7 · Cited by 600 · cited 1×
“Comparative analysis of NRM is additionally complicated when considering the intrinsic heterogeneity of the infusion product itself 83 .”
Schuster, S. J., Tam, C. S., Borchmann, P., Worel, N., McGuirk, J. P., Holte, H., Waller, E. K., Jaglowski, S., Bishop, M. R., Damon, L. E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00375-2 · Cited by 584
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
Hill, J. A., Li, D., Hay, K. A., Green, M. L., Cherian, S., Chen, X., Riddell, S. R., Maloney, D. G., Boeckh, M., & Turtle, C. J. (2018) · Blood · doi:10.1182/blood-2017-07-793760 · Cited by 576
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
Bishop, M. R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., Kato, K., Sureda, A., Greil, R., Thieblemont, C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116596 · Cited by 538
A LIKELIHOOD APPROACH TO META-ANALYSIS WITH RANDOM EFFECTS
HARDY, R. J., & THOMPSON, S. G. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19960330)15:6<619::aid-sim188>3.0.co;2-a · Cited by 522
Rejeski, K., Perez, A., Sesques, P., Hoster, E., Berger, C., Jentzsch, L., Mougiakakos, D., Frölich, L., Ackermann, J., Bücklein, V., et al. (2021) · Blood · doi:10.1182/blood.2020010543 · Cited by 475
Self-citationSurvival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Westin, J. R., Oluwole, O. O., Kersten, M. J., Miklos, D. B., Perales, M.-A., Ghobadi, A., Rapoport, A. P., Sureda, A., Jacobson, C. A., Farooq, U., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301665 · Cited by 455
Self-citationCAR T-cell therapy in autoimmune diseases
Schett, G., Mackensen, A., & Mougiakakos, D. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01126-1 · Cited by 430
Bachy, E., Le Gouill, S., Di Blasi, R., Sesques, P., Manson, G., Cartron, G., Beauvais, D., Roulin, L., Gros, F. X., Rubio, M. T., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01969-y · Cited by 405
Abramson, J. S., Solomon, S. R., Arnason, J., Johnston, P. B., Glass, B., Bachanova, V., Ibrahimi, S., Mielke, S., Mutsaers, P., Hernandez-Ilizaliturri, F., et al. (2023) · Blood · doi:10.1182/blood.2022018730 · Cited by 399
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
Cordeiro, A., Bezerra, E. D., Hirayama, A. V., Hill, J. A., Wu, Q. V., Voutsinas, J., Sorror, M. L., Turtle, C. J., Maloney, D. G., & Bar, M. (2020) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2019.08.003 · Cited by 364
Rejeski, K., Subklewe, M., Aljurf, M., Bachy, E., Balduzzi, A., Barba, P., Bruno, B., Benjamin, R., Carrabba, M. G., Chabannon, C., et al. (2023) · Blood · doi:10.1182/blood.2023020578 · Cited by 358
Self-citationKarschnia, P., Jordan, J. T., Forst, D. A., Arrillaga-Romany, I. C., Batchelor, T. T., Baehring, J. M., Clement, N. F., Gonzalez Castro, L. N., Herlopian, A., Maus, M. V., et al. (2019) · Blood · doi:10.1182/blood-2018-12-893396 · Cited by 351
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01702-9 · Cited by 349 · cited 1×
“Indeed, both host factors (for example, performance status, comorbidities) and disease-specific factors (for example, tumor load, systemic inflammation) could have contributed to the observed variation of NRM rates across CAR T cell products 28,78–81 .”
Self-citationImmune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome
Hines, M. R., Knight, T. E., McNerney, K. O., Leick, M. B., Jain, T., Ahmed, S., Frigault, M. J., Hill, J. A., Jain, M. D., Johnson, W. T., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.03.006 · Cited by 338
Self-citationWang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.21.02370 · Cited by 331
Real-world data: towards achieving the achievable in cancer care
Booth, C. M., Karim, S., & Mackillop, W. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0167-7 · Cited by 327
Systematic review and meta-analysis methodology
Crowther, M., Lim, W., & Crowther, M. A. (2010) · Blood · doi:10.1182/blood-2010-05-280883 · Cited by 306
Hill, J. A., & Seo, S. K. (2020) · Blood · doi:10.1182/blood.2019004000 · Cited by 305
Hansen, D. K., Sidana, S., Peres, L. C., Colin Leitzinger, C., Shune, L., Shrewsbury, A., Gonzalez, R., Sborov, D. W., Wagner, C., Dima, D., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01365 · Cited by 293
Neelapu, S. S., Dickinson, M., Munoz, J., Ulrickson, M. L., Thieblemont, C., Oluwole, O. O., Herrera, A. F., Ujjani, C. S., Lin, Y., Riedell, P. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01731-4 · Cited by 291
McDonald, G. B., Sandmaier, B. M., Mielcarek, M., Sorror, M., Pergam, S. A., Cheng, G.-S., Hingorani, S., Boeckh, M., Flowers, M. D., Lee, S. J., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m19-2936 · Cited by 285
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Ghilardi, G., Fraietta, J. A., Gerson, J. N., Van Deerlin, V. M., Morrissette, J. J. D., Caponetti, G. C., Paruzzo, L., Harris, J. C., Chong, E. A., Susanibar Adaniya, S. P., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02826-w · Cited by 270
Jain, T., Knezevic, A., Pennisi, M., Chen, Y., Ruiz, J. D., Purdon, T. J., Devlin, S. M., Smith, M., Shah, G. L., Halton, E., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002509 · Cited by 269
Self-citationSehgal, A., Hoda, D., Riedell, P. A., Ghosh, N., Hamadani, M., Hildebrandt, G. C., Godwin, J. E., Reagan, P. M., Wagner-Johnston, N., Essell, J., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00339-4 · Cited by 242
Neelapu, S. S., Jacobson, C. A., Ghobadi, A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2023) · Blood · doi:10.1182/blood.2022018893 · Cited by 242
Garfall, A. L., Dancy, E. K., Cohen, A. D., Hwang, W.-T., Fraietta, J. A., Davis, M. M., Levine, B. L., Siegel, D. L., Stadtmauer, E. A., Vogl, D. T., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000600 · Cited by 226
Strati, P., Ahmed, S., Furqan, F., Fayad, L. E., Lee, H. J., Iyer, S. P., Nair, R., Nastoupil, L. J., Parmar, S., Rodriguez, M. A., et al. (2021) · Blood · doi:10.1182/blood.2020008865 · Cited by 218
GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany
Bethge, W. A., Martus, P., Schmitt, M., Holtick, U., Subklewe, M., von Tresckow, B., Ayuk, F., Wagner-Drouet, E. M., Wulf, G. G., Marks, R., et al. (2022) · Blood · doi:10.1182/blood.2021015209 · Cited by 214
Self-citationRejeski, K., Perez, A., Iacoboni, G., Penack, O., Bücklein, V., Jentzsch, L., Mougiakakos, D., Johnson, G., Arciola, B., Carpio, C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004475 · Cited by 202
Self-citationUnanswered questions following reports of secondary malignancies after CAR-T cell therapy
Levine, B. L., Pasquini, M. C., Connolly, J. E., Porter, D. L., Gustafson, M. P., Boelens, J. J., Horwitz, E. M., Grupp, S. A., Maus, M. V., Locke, F. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02767-w · Cited by 201
Self-citationWang, Y., Jain, P., Locke, F. L., Maurer, M. J., Frank, M. J., Munoz, J. L., Dahiya, S., Beitinjaneh, A. M., Jacobs, M. T., Mcguirk, J. P., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01797 · Cited by 191
Jacobson, C. A., Locke, F. L., Ma, L., Asubonteng, J., Hu, Z.-H., Siddiqi, T., Ahmed, S., Ghobadi, A., Miklos, D. B., Lin, Y., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.05.026 · Cited by 186
Self-citationRejeski, K., Hansen, D. K., Bansal, R., Sesques, P., Ailawadhi, S., Logue, J. M., Bräunlein, E., dos Santos, D. M. C., Freeman, C. L. L., Alsina, M., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01465-x · Cited by 168
Self-citationAdverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy
Goldman, A., Maor, E., Bomze, D., Liu, J. E., Herrmann, J., Fein, J. A., Steingart, R. M., Mahmood, S., Schaffer, W. L., Perales, M., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.044 · Cited by 161
Self-citationAxicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Kwon, M., Iacoboni, G., Reguera, J. L., López‐Corral, L., Hernani, R., Ortiz‐Maldonado, V., Guerreiro, M., Caballero, A. C., Guerra-Domínguez, M. L., Pina, J. M. S., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280805 · Cited by 157
Wudhikarn, K., Pennisi, M., García‐Recio, M., Flynn, J. R., Afuye, A. O., Silverberg, M. L., Maloy, M., Devlin, S. M., Batlevi, C. L., Shah, G. L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001972 · Cited by 152
Self-citationLin, Y., Raje, N. S., Berdeja, J. G., Siegel, D. S. D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J. M., Maus, M. V., Massaro, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02496-0 · Cited by 143
Infections after chimeric antigen receptor (CAR)‐T‐cell therapy for hematologic malignancies
Kampouri, E., Little, J. S., Rejeski, K., Manuel, O., Hammond, S. P., & Hill, J. A. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14157 · Cited by 143
Self-citationFerreri, C. J., Hildebrandt, M. A. T., Hashmi, H., Shune, L. O., McGuirk, J. P., Sborov, D. W., Wagner, C. B., Kocoglu, M. H., Rapoport, A. P., Atrash, S., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00886-8 · Cited by 142
Locke, F. L., Filosto, S., Chou, J., Vardhanabhuti, S., Perbost, R., Dreger, P., Hill, B. T., Lee, C. J., Zinzani, P. L., Kröger, N. M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02754-1 · Cited by 140
A national service for delivering CD19 CAR‐T in large B‐cell lymphoma – The UK real‐world experience
Kühnl, A., Roddie, C., Kirkwood, A. A., Tholouli, E., Menne, T., Patel, A. K., Besley, C., Chaganti, S., Sanderson, R., O'Reilly, M. A., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18209 · Cited by 133
Clonal Hematopoiesis: Mechanisms Driving Dominance of Stem Cell Clones
Challen, G., & Goodell, M. A. (2020) · Blood · doi:10.1182/blood.2020006510 · Cited by 131 · cited 1×
“Nevertheless, considering the growing body of evidence elucidating the role of inflammatory stressors for clonal expansion 100,101 , the impact of CAR T cell-induced inflammatory stress on the development of secondary myeloid malignancies warrants future systematic study.”
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy
Miller, P. G., Sperling, A. S., Brea, E. J., Leick, M. B., Fell, G. G., Jan, M., Gohil, S. H., Tai, Y.-T., Munshi, N. C., Wu, C. J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004554 · Cited by 131
Houot, R., Bachy, E., Cartron, G., Gros, F., Morschhauser, F., Obéric, L., Gastinne, T., Feugier, P., Duléry, R., Thiéblemont, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02572-5 · Cited by 128
Dreyling, M. H., Fowler, N. H., Dickinson, M. J., Martínez‐López, J., Kolstad, A., Butler, J., Ghosh, M., Popplewell, L. L., Chávez, J. C., Bachy, E., et al. (2024) · Blood · doi:10.1182/blood.2023021567 · Cited by 124
Clonal hematopoiesis and associated diseases: A review of recent findings
Asada, S., & Kitamura, T. (2021) · Cancer Science · doi:10.1111/cas.15094 · Cited by 111
Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells
Karschnia, P., Miller, K. C., Yee, A. J., Rejeski, K., Johnson, P. C., Raje, N. S., Frigault, M. J., & Dietrich, J. (2023) · Blood · doi:10.1182/blood.2023020571 · Cited by 103
Self-citationIacoboni, G., Rejeski, K., Villacampa, G. J., van Doesum, J. A., Chiappella, A., Bonifazi, F., López‐Corral, L., van Aalderen, M. C., Kwon, M., Martínez‐Cibrián, N., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006922 · Cited by 100
Self-citationSecond Malignancies after Hematopoietic Stem Cell Transplantation
Danylesko, I., & Shimoni, A. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0528-y · Cited by 97
Lemoine, J., Bachy, E., Cartron, G., Beauvais, D., Gastinne, T., Blasi, R. D., Rubio, M., Guidez, S., Mohty, M., Casasnovas, O., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010624 · Cited by 94
Rejeski, K., Jain, M. D., & Smith, E. L. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.04.007 · Cited by 93
Self-citationRejeski, K., Wang, Y., Hansen, D. K., Iacoboni, G., Bachy, E., Bansal, R., Penack, O., Müller, F., Bethge, W. A., Munoz, J. L., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011767 · Cited by 92
Self-citationRiedell, P. A., Hwang, W., Nastoupil, L. J., Pennisi, M., McGuirk, J. P., Maziarz, R. T., Bachanová, V., Oluwole, O. O., Brower, J., Flores, O. A., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.07.011 · Cited by 88
Self-citationLiévin, R., Blasi, R. D., Morin, F., Galli, E., Allain, V., de Jorna, R., Vercellino, L., Parquet, N., Mebarki, M., Larghero, J., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01526-0 · Cited by 82
Mi, J., Zhao, W., Jing, H., Fu, W., Hu, J., Chen, L., Zhang, Y., Yao, D., Chen, D., Schecter, J. M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00690 · Cited by 82
Busca, A., Salmanton‐García, J., Corradini, P., Marchesi, F., Cabirta, A., Blasi, R. D., Duléry, R., Lamure, S., Farina, F., Weinbergerová, B., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005616 · Cited by 81
Goodman, K. A., Riedel, E., Serrano, V., Gulati, S. C., Moskowitz, C. H., & Yahalom, J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5507 · Cited by 72
Gudiol, C., Lewis, R. E., Strati, P., & Kontoyiannis, D. P. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30376-8 · Cited by 72
Fischer, L., Grieb, N., Born, P., Weiss, R., Seiffert, S., Boldt, A., Fricke, S., Franz, P., Heyn, S., Kubasch, A. S., et al. (2024) · Leukemia · doi:10.1038/s41375-023-02129-y · Cited by 69
Rejeski, K., Wang, Y., Albanyan, O., Munoz, J. L., Sesques, P., Iacoboni, G., López‐Corral, L., Ries, I., Bücklein, V., Mohty, R., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27056 · Cited by 68
Self-citationRejeski, K., Perez, A. P., Iacoboni, G., Blumenberg, V., Bücklein, V., Völkl, S., Penack, O., Albanyan, O., Stock, S., Müller, F., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg3919 · Cited by 68
Self-citationLate Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies
Chakraborty, R., Hill, B. T., Majeed, A., & Majhail, N. S. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2020.10.002 · Cited by 67
Brammer, J. E., Braunstein, Z., Katapadi, A., Porter, K. M., Biersmith, M. A., Guha, A., Vasu, S., Yildiz, V. O., Smith, S. A., Buck, B. H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002303 · Cited by 66
Rejeski, K., Greco, R., Onida, F., Sánchez‐Ortega, I., Bonini, C., Sureda, A. M., Gribben, J. G., Yakoub‐Agha, I., & Subklewe, M. S. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000889 · Cited by 65
Self-citationFilosto, S., Vardhanabhuti, S., Canales, M. Á., Poiré, X., Lekakis, L. J., de Vos, S., Portell, C. A., Wang, Z., To, C., Schupp, M., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0112 · Cited by 64
Rejeski, K., dos Santos, D. M. C., Parker, N. H., Bücklein, V., Winkelmann, M., Jhaveri, K. S., Liu, L., Trinkner, P., Günther, S., Karschnia, P., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0487 · Cited by 62
Self-citationShouse, G., Kaempf, A. J., Gordon, M. J., Artz, A. S., Yashar, D., Sigmund, A. M., Smilnak, G., Bair, S. M., Mian, A., Fitzgerald, L. A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009309 · Cited by 60
Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma
Hashmi, H., Mirza, A., Darwin, A. H., Logothetis, C., Garcia, F., Kommalapati, A., Mhaskar, R. S., Bachmeier, C. A., Chávez, J. C., Shah, B. D., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002060 · Cited by 59
Saleem, K., Franz, J. K., Klem, M. L., Yabes, J. G., Boyiadzis, M. M., Jones, J. R., Shaikh, N., & Lontos, K. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00289-7 · Cited by 57
Bias in reporting of randomised clinical trials in oncology
Vera-Badillo, F., Napoleone, M., Krzyzanowska, M. K., Alibhai, S. M. H., Chan, A., Ocaña, A., Šeruga, B., Templeton, A. J., Amir, E., & Tannock, I. F. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.066 · Cited by 54
dos Santos, D. M. C., Rejeski, K., Winkelmann, M., Liu, L., Trinkner, P., Günther, S., Bücklein, V., Blumenberg, V., Schmidt, C., Kunz, W. G., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.280189 · Cited by 52
Self-citationLittle, J. S., Tandon, M., Hong, J., Nadeem, O., Sperling, A. S., Raje, N. S., Munshi, N. C., Frigault, M. J., Barmettler, S., & Hammond, S. P. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010524 · Cited by 50
Berning, P., Shumilov, E., Maulhardt, M., Boyadzhiev, H., Kerkhoff, A., Call, S., Reicherts, C., Saidy, A. O., Aydilek, E., Hoffmann, M., et al. (2024) · HemaSphere · doi:10.1002/hem3.54 · Cited by 50
Wudhikarn, K., Tomás, A. A., Flynn, J. R., Devlin, S. M., Brower, J., Bachanová, V., Nastoupil, L. J., McGuirk, J. P., Maziarz, R. T., Oluwole, O. O., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008294 · Cited by 46
Self-citationClinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
Panagiota, V., Kerschbaum, J. F., Penack, O., Stein, C. M., Arends, C. M., Koenecke, C., Strzelecka, P. M., Kloos, A., Wiegand, L., Lasch, A., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000957 · Cited by 46
Zhao, A., Zhao, M., Qian, W., Liang, A., Li, P., & Liu, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1063986 · Cited by 39
Bücklein, V., Perez, A. P., Rejeski, K., Iacoboni, G., Jurinović, V., Holtick, U., Penack, O., Kharboutli, S., Blumenberg, V., Ackermann, J., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000907 · Cited by 38
Self-citationChiappella, A., Casadei, B., Chiusolo, P., Rocco, A. D., Ljevar, S., Magni, M., Angelillo, P., Barbui, A. M., Cutini, I., Dodero, A., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02213-x · Cited by 38
Hamilton, M. P., Craig, E. M., Sanchez, C. G., Mina, A. A., Tamaresis, J. S., Kirmani, N., Ehlinger, Z. J., Syal, S., Good, Z., Sworder, B. J., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012637 · Cited by 35
Chaer, F. E., Auletta, J. J., & Chemaly, R. F. (2022) · Blood · doi:10.1182/blood.2022016089 · Cited by 30
Akhtar, O. S., Modi, K., Kim, J., Skelson, L., Smith, E., Al‐Jumayli, M., Extermann, M., Avila, G. D., Parker, N. H., Puglianini, O. A. C., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.12.010 · Cited by 30
Kato, K., Makita, S., Goto, H., Kanda, J., Fujii, N., Shimada, K., Akashi, K., Izutsu, K., Teshima, T., Fukuda, N., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02033-4 · Cited by 27
Spanjaart, A. M., Pennings, E. R. A., Mutsaers, P., van Dorp, S., Jak, M., van Doesum, J. A., de Boer, J., Niezink, A. G. H., Kos, M., Vermaat, J. S. P., et al. (2023) · Cancers · doi:10.3390/cancers15174334 · Cited by 26
Jacobs, M. T., Jain, M. D., Gao, F., Nastoupil, L. J., Spiegel, J. Y., Lin, Y., Dahiya, S., Lunning, M. A., Lekakis, L. J., Reagan, P. M., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.05.004 · Cited by 22
Improved outcomes of large B‐cell lymphoma patients treated with CD19 CAR T in the UK over time
Boyle, S., Roddie, C., O'Reilly, M. A., Menne, T., Norman, J. E., Gibb, A., Lugthart, S., Chaganti, S., Arias, C. G., Jones, C. H., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19157 · Cited by 22
Trando, A., Ter‐Zakarian, A., Yeung, P., Goodman, A. M., Hamdan, A., Hurley, M. P., Jeong, A., & Tzachanis, D. (2023) · Cancers · doi:10.3390/cancers15184671 · Cited by 21
Caillot, L., Sleiman, E., Lafon, I., Chrétien, M., Gueneau, P., Payssot, A., Pedri, R., Lakomy, D., Bailly, F., Guy, J., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.03.003 · Cited by 17
Iovino, L., Wu, Q. V., Voutsinas, J. M., Panaite, L., Mullane, E., Lynch, R. C., Ujjani, C. S., Smith, S. D., Gopal, A. K., Till, B. G., et al. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17550 · Cited by 16
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma
Chong, E. A., Chong, E. A., Therwhanger, D., Nasta, S. D., Landsburg, D. J., Nasta, S. D., Svoboda, J., Gerson, J. N., Ghilardi, G., Paruzzo, L., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.03.015 · Cited by 11
Hadidi, S. A., & Cliff, E. R. S. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.018 · Cited by 6
Self-citation
Cited by
Genomic landscape of multiple myeloma and its precursor conditions
Alberge, J.-B., Dutta, A. K., Poletti, A., Coorens, T. H. H., Lightbody, E. D., Toenges, R., Loinaz, X., Wallin, S., Dunford, A., Priebe, O., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02196-0 · Cited by 32
Self-citationLin, X., Liu, J., Chen, J., Tang, J., Huang, Z., Wang, Y., & Shi, S. (2026) · Asia-Pacific Journal of Oncology Nursing · doi:10.1016/j.apjon.2025.100850 · Cited by 3
Metadata
- Authors
- Cordas dos Santos, D. M., Tix, T., Shouval, R., Gafter-Gvili, A., Alberge, J.-B., Cliff, E. R. S., Theurich, S., von Bergwelt-Baildon, M., Ghobrial, I. M., Subklewe, M., Perales, M.-A., & Rejeski, K.
- Venue
- Nature Medicine
- Published
- 2024-07-08
- Volume
- 30
- Issue
- 9
- Pages
- 2667-2678
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4400423444
- Cited by
- 287
- References
- 113
- FWCI
- 23.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.